Annual EBITDA
-$54.34 M
+$9.61 M+15.03%
December 31, 2024
Summary
- As of March 14, 2025, NXTC annual EBITDA is -$54.34 million, with the most recent change of +$9.61 million (+15.03%) on December 31, 2024.
- During the last 3 years, NXTC annual EBITDA has risen by +$12.25 million (+18.39%).
- NXTC annual EBITDA is now -263.07% below its all-time high of -$14.97 million, reached on December 31, 2017.
Performance
NXTC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$11.78 M
+$14.00 K+0.12%
December 31, 2024
Summary
- As of March 14, 2025, NXTC quarterly EBITDA is -$11.78 million, with the most recent change of +$14.00 thousand (+0.12%) on December 31, 2024.
- Over the past year, NXTC quarterly EBITDA has increased by +$3.19 million (+21.28%).
- NXTC quarterly EBITDA is now -231.44% below its all-time high of $8.96 million, reached on March 31, 2020.
Performance
NXTC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$54.34 M
+$3.19 M+5.54%
December 31, 2024
Summary
- As of March 14, 2025, NXTC TTM EBITDA is -$54.34 million, with the most recent change of +$3.19 million (+5.54%) on December 31, 2024.
- Over the past year, NXTC TTM EBITDA has increased by +$9.61 million (+15.03%).
- NXTC TTM EBITDA is now -1072.91% below its all-time high of -$4.63 million, reached on March 31, 2018.
Performance
NXTC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NXTC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.0% | +21.3% | +15.0% |
| 3 y3 years | +18.4% | +26.5% | +18.4% |
| 5 y5 years | -56.2% | -4.7% | -56.2% |
NXTC EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +24.3% | at high | +40.2% | at high | +24.3% |
| 5 y | 5-year | -56.2% | +24.3% | -231.4% | +40.2% | -177.6% | +24.3% |
| alltime | all time | -263.1% | +24.3% | -231.4% | +40.2% | -1072.9% | +24.3% |
NextCure EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$54.34 M(-15.0%) | -$11.78 M(-0.1%) | -$54.34 M(-5.5%) |
| Sep 2024 | - | -$11.79 M(-25.3%) | -$57.53 M(-4.8%) |
| Jun 2024 | - | -$15.79 M(+5.5%) | -$60.40 M(-3.8%) |
| Mar 2024 | - | -$14.97 M(+0.0%) | -$62.81 M(-1.8%) |
| Dec 2023 | -$63.95 M(-10.9%) | -$14.97 M(+2.0%) | -$63.95 M(-2.7%) |
| Sep 2023 | - | -$14.67 M(-19.4%) | -$65.75 M(-5.1%) |
| Jun 2023 | - | -$18.20 M(+13.0%) | -$69.30 M(+1.6%) |
| Mar 2023 | - | -$16.11 M(-3.9%) | -$68.18 M(-5.0%) |
| Dec 2022 | -$71.78 M(+7.8%) | -$16.76 M(-8.0%) | -$71.78 M(+1.0%) |
| Sep 2022 | - | -$18.22 M(+6.6%) | -$71.05 M(+2.1%) |
| Jun 2022 | - | -$17.09 M(-13.3%) | -$69.60 M(-0.8%) |
| Mar 2022 | - | -$19.71 M(+23.0%) | -$70.17 M(+5.4%) |
| Dec 2021 | -$66.59 M | -$16.03 M(-4.4%) | -$66.59 M(+1.2%) |
| Sep 2021 | - | -$16.77 M(-5.1%) | -$65.81 M(+0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$17.66 M(+9.5%) | -$65.55 M(+4.2%) |
| Mar 2021 | - | -$16.13 M(+5.8%) | -$62.90 M(+66.4%) |
| Dec 2020 | -$37.81 M(+8.7%) | -$15.25 M(-7.7%) | -$37.81 M(+11.8%) |
| Sep 2020 | - | -$16.51 M(+10.0%) | -$33.82 M(+29.0%) |
| Jun 2020 | - | -$15.01 M(-267.5%) | -$26.22 M(+33.9%) |
| Mar 2020 | - | $8.96 M(-179.6%) | -$19.58 M(-43.7%) |
| Dec 2019 | -$34.79 M(+61.7%) | -$11.26 M(+26.3%) | -$34.79 M(+15.6%) |
| Sep 2019 | - | -$8.91 M(+6.5%) | -$30.09 M(+13.1%) |
| Jun 2019 | - | -$8.37 M(+33.9%) | -$26.60 M(+15.0%) |
| Mar 2019 | - | -$6.25 M(-4.5%) | -$23.14 M(+7.5%) |
| Dec 2018 | -$21.52 M(+43.8%) | -$6.55 M(+20.7%) | -$21.52 M(+43.7%) |
| Sep 2018 | - | -$5.42 M(+10.4%) | -$14.97 M(+56.8%) |
| Jun 2018 | - | -$4.91 M(+6.0%) | -$9.55 M(+106.0%) |
| Mar 2018 | - | -$4.63 M | -$4.63 M |
| Dec 2017 | -$14.97 M | - | - |
FAQ
- What is NextCure annual EBITDA?
- What is the all time high annual EBITDA for NextCure?
- What is NextCure annual EBITDA year-on-year change?
- What is NextCure quarterly EBITDA?
- What is the all time high quarterly EBITDA for NextCure?
- What is NextCure quarterly EBITDA year-on-year change?
- What is NextCure TTM EBITDA?
- What is the all time high TTM EBITDA for NextCure?
- What is NextCure TTM EBITDA year-on-year change?
What is NextCure annual EBITDA?
The current annual EBITDA of NXTC is -$54.34 M
What is the all time high annual EBITDA for NextCure?
NextCure all-time high annual EBITDA is -$14.97 M
What is NextCure annual EBITDA year-on-year change?
Over the past year, NXTC annual EBITDA has changed by +$9.61 M (+15.03%)
What is NextCure quarterly EBITDA?
The current quarterly EBITDA of NXTC is -$11.78 M
What is the all time high quarterly EBITDA for NextCure?
NextCure all-time high quarterly EBITDA is $8.96 M
What is NextCure quarterly EBITDA year-on-year change?
Over the past year, NXTC quarterly EBITDA has changed by +$3.19 M (+21.28%)
What is NextCure TTM EBITDA?
The current TTM EBITDA of NXTC is -$54.34 M
What is the all time high TTM EBITDA for NextCure?
NextCure all-time high TTM EBITDA is -$4.63 M
What is NextCure TTM EBITDA year-on-year change?
Over the past year, NXTC TTM EBITDA has changed by +$9.61 M (+15.03%)